Development and validation of a new risk score for infection with coronavirus (Ri.S.I.Co) obtained from treating coronavirus disease (COVID-19) patients on the field
Joint Authors
Fugazzola, Paola
Casadei, Chiara
Favi, Francesco
Tomasoni, Matteo
Zaghi, Claudia
Prosperi, Enrico
Sermonesi, Giacomo
Corbella, Davide
Pratico, Beniamino
Coccolini, Federico
Agnoletti, Vanni
Ansaloni, Luca
Source
Iranian Red Crescent Medical Journal
Issue
Vol. 22, Issue 7 (31 Jul. 2020), pp.1-12, 12 p.
Publisher
Publication Date
2020-07-31
Country of Publication
United Arab Emirates
No. of Pages
12
Main Subjects
Abstract EN
Background: The Coronavirus Disease 2019 (COVID-19) pandemic has necessitated the alteration of the organization of entire hos- pitals to try to prevent them from becoming epidemiological clusters.
The adopted diagnostic tools lack sensitivity or specificity.
Objectives: The aim of the study was to create an easy-to-get risk score (Ri.S.I.Co., risk score for infection with the new coronavirus) developed on the field to stratify patients admitted to hospitals according to their risk of COVID-19 infection.
Methods: In this prospective study, we included all patients who were consecutively admitted to the suspected COVID-19 depart- ment of the Bufalini Hospital, Cesena (Italy).
All clinical, radiological, and laboratory predictors were included in the multivariate logistic regression model to create a risk model.
A simplified model was internally and externally validated, and two score thresh- olds for stratifying the probability of COVID-19 infection were introduced.
Results: From 11th March to 5th April 2020, 200 patients were consecutively admitted.
A Ri.S.I.Co lower than 2 showed a higher sensitivity than SARS-Cov-2 nucleic acid detection (96.2% vs.
65.4%; P < 0.001).
The presence of ground-glass pattern on the lung-CT scan had a lower sensitivity than a Ri.S.I.Co lower than 2 (88.5% vs.
96.2%; P < 0.001) and a lower specificity than a Ri.S.I.Co higher than 6 (75.0% vs.
96.9%; P < 0.001).
Conclusions: We believe that the Ri.S.I.Co could allow to stratify admitted patients according to their risk, preventing hospitals from becoming the main COVID-19 carriers themselves.
Furthermore, it could guide clinicians in starting therapies early in severe- onset cases with a high probability of COVID-19, before molecular SARS-CoV-2 infection is confirmed.
American Psychological Association (APA)
Fugazzola, Paola& Favi, Francesco& Tomasoni, Matteo& Zaghi, Claudia& Casadei, Chiara& Ansaloni, Luca…[et al.]. 2020. Development and validation of a new risk score for infection with coronavirus (Ri.S.I.Co) obtained from treating coronavirus disease (COVID-19) patients on the field. Iranian Red Crescent Medical Journal،Vol. 22, no. 7, pp.1-12.
https://search.emarefa.net/detail/BIM-1430509
Modern Language Association (MLA)
Ansaloni, Luca…[et al.]. Development and validation of a new risk score for infection with coronavirus (Ri.S.I.Co) obtained from treating coronavirus disease (COVID-19) patients on the field. Iranian Red Crescent Medical Journal Vol. 22, no. 7 (Jul. 2020), pp.1-12.
https://search.emarefa.net/detail/BIM-1430509
American Medical Association (AMA)
Fugazzola, Paola& Favi, Francesco& Tomasoni, Matteo& Zaghi, Claudia& Casadei, Chiara& Ansaloni, Luca…[et al.]. Development and validation of a new risk score for infection with coronavirus (Ri.S.I.Co) obtained from treating coronavirus disease (COVID-19) patients on the field. Iranian Red Crescent Medical Journal. 2020. Vol. 22, no. 7, pp.1-12.
https://search.emarefa.net/detail/BIM-1430509
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 11-12
Record ID
BIM-1430509